News
CERS
1.655
+0.91%
0.015
Press Release: Cerus Corporation to Release First Quarter 2024 Financial Results on May 2, 2024
Cerus Corporation to Release First Quarter 2024 Financial Results on May 2, 2024. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon. Management will discuss the Company's financial results and provide a general business overview. Cerus is dedicated to safeguarding the world's blood supply.
Dow Jones · 5h ago
Cerus Corporation to Release First Quarter 2024 Financial Results on May 2, 2024
Cerus Corporation's first quarter 2024 financial results will be released on Thursday, May 2, 2024. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon. Cerus is dedicated solely to safeguarding the world’s blood supply.
Barchart · 10h ago
Weekly Report: what happened at CERS last week (0408-0412)?
Weekly Report · 3d ago
Cerus gains as Craig Hallum launches at Buy on return to growth
Seeking Alpha · 6d ago
Cerus Corporation: Strong Buy Rating Amidst Growth and Path to Profitability
TipRanks · 6d ago
Cerus Initiated at Buy by Craig-Hallum
Dow Jones · 6d ago
Cerus Price Target Announced at $5.00/Share by Craig-Hallum
Dow Jones · 6d ago
Craig-Hallum Initiates Coverage On Cerus with Buy Rating, Announces Price Target of $5
Benzinga · 6d ago
CERUS CORP <CERS.O>: CRAIG-HALLUM INITIATES COVERAGE WITH BUY RATING; TARGET PRICE $5
Reuters · 6d ago
Perion Network Cuts Sales Outlook, Joins Range Resources And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Shares of Perion Network Ltd. (NASDAQ:PERI) fell sharply in today's pre-market trading after the company slashed FY24 revenue guidance. The Dow futures fell by around 10 points on Monday. U.S. Stock futures were mixed in today’s trading session.
Benzinga · 04/08 12:24
Weekly Report: what happened at CERS last week (0401-0405)?
Weekly Report · 04/08 11:32
Weekly Report: what happened at CERS last week (0325-0329)?
Weekly Report · 04/01 11:30
Cerus Corporation Announces FDA Approval Of Extended Shelf Life For INTERCEPT Platelet Processing Sets, Doubling Previous Shelf Life
U.S. Food and Drug Administration grants approval of 12-month shelf life for INTERCEPT Platelet Processing Sets. This approval extends the set shelf life by six months from the existing six-month extension. All INTERCEPT Processing Sets in customer and Cerus inventories are eligible for the extension. The Company is continuing to pursue shelf life extension.
Benzinga · 03/26 12:31
Weekly Report: what happened at CERS last week (0318-0322)?
Weekly Report · 03/25 11:33
Cathie Wood's Ark Invest Sells Another Tranche Of Block Shares, Even As Bitcoin Price Stages A Recovery
Cathie Wood-led Ark Invest sold 42,608 shares of Block Inc for $3.5 million on Wednesday. The firm has sold Block shares in every trading session of the current week. The Block Inc trade comes amid Bitcoin prices recovering. Ark has also sold shares of Cerus Corp, Personalis and Moderna.
Benzinga · 03/21 03:40
Wednesday's ETF Movers: ILF, ARKG
NASDAQ · 03/20 16:35
Why Blood Components-Focused Cerus Stock Is Rising Tuesday
Cerus Corporation announces topline results for the ReCePI Phase 3 trial of pathogen-reduced INTERCEPT Red Blood Cells. The INTERCEPT Blood System is designed to inactivate blood-borne pathogens and donor leukocytes in RBCs intended for transfusion.
Benzinga · 03/19 18:39
Cerus Shares Rise on Positive Results for Intercept Blood Cells Trial
Shares of Cerus rose 10% to $2.05 in the first few hours of the trading day. Positive results were disclosed in a Phase 3 trial of its INTERCEPT Red Blood Cells being transfused to complex cardiac surgery patients. Cerus anticipated initiating a premarket approval application in the second half of 2014.
Dow Jones · 03/19 15:57
Cerus' late stage trial for INTERCEPT RBCs in heart surgery patients met main goal
Healthcare Cerus' late stage trial for INTERCEPT RBCs in heart surgery patients met main goal. The trial demonstrated non-inferiority of the incidence of acute kidney injury. Cerus anticipates initiating a modular PMA application to the FDA in the second half of 2025.
Seeking Alpha · 03/19 12:47
Market-Moving News for March 19th
Cerus and Hoth Therapeutics are both up. Crinetics Pharmaceuticals shares are trading higher. The company's Phase 3 trial of paltusotine in acromegaly achieved the primary and all secondary endpoints. Cerus shares are up 64% in premarket trading.
Benzinga · 03/19 12:41
More
Webull provides a variety of real-time CERS stock news. You can receive the latest news about Cerus through multiple platforms. This information may help you make smarter investment decisions.
About CERS
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.